Navigation Links
China's Type 2 Diabetes Drug Market Will More than Triple by 2012
Date:5/28/2008

New Entries to China Drug Market to Garner More Than $270 Million in

Combined Sales, According to a New Report by Decision Resources

WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese type 2 diabetes drug market will more than triple by 2012. According to the new Emerging Markets report entitled Type 2 Diabetes in China, this growth will be fueled by increased access to health insurance, greater patient spending power and more aggressive treatment practice, leading to increased usage of newer agents such as the insulin analogues. Additionally, the number of prevalent cases of type 2 diabetes in China is among the highest in the world -- 62.5 million cases in 2007 -- a number that rivals that of the United States, Europe and Japan combined (48.5 million cases). The high prevalence rate in China reflects an aging population and urbanization-associated risk factors, such as diet and lack of physical activities.

"The Chinese government and medical associations are promoting guidelines published by the American Diabetes Association, the World Health Organization and the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst at Decision Resources. "All guidelines advocate earlier and more-aggressive interventions in type 2 diabetes patients. We forecast that the patient population treated with polypharmacy will nearly double between 2007 and 2012."

The report also finds that three new type 2 diabetes agents with novel mechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis's Galvus -- are expected to launch in China by 2012. The combined sales of these three agents will surpass $270 million by 2012. However, the high cost of many antidiabetic therapies, particularly Western-branded drugs, is a major barrier to effective management of type 2 diabetes in China. Patient ability to pay for medications influences physician prescribing habits, particularly prescription of newer drugs such as the peroxisome proliferator-activated receptor (PPAR)-gamma agonists and the insulin analogues, which are not reimbursed or are only partially reimbursed in some provinces.

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

-- More accurately assess the commercial opportunity for Western brands in

key pharmaceutical markets of China -- Beijing, Shanghai,

Guangzhou -- and in the high-growth second-tier markets of Tianjin,

Wuhan, Nanjing, Hangzhou, and Jinan.

-- Understand the physician treatment patterns and drivers of choice in

key first- and second-tier cities based on primary research.

-- Gain a clear perspective of the Chinese five-year market forecast at

the drug level, broken out by urban and rural areas, and by sales from

multinational and Chinese-based companies.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
2. New insights in diagnosing diabetes may help the millions who are undiagnosed
3. Rhinestone Cure Sets the Glitz to Benefit Diabetes at Hotel Indigo
4. New Antioxidant Drug Shows Promise Against Diabetes
5. Lifestyle Changes Can Keep Diabetes at Bay for 14 Years
6. Anti-rejection drug may increase risk of diabetes after kidney transplant
7. Study: Doctors not always sure when to treat BP in people with diabetes
8. Study: Doctors Not Always Sure When to Treat Blood Pressure in People With Diabetes
9. Seattle Laces Up To Beat the Bridge and Diabetes
10. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
11. American Diabetes Wholesale Launches Affiliate Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and adults ... and achievable answer. “The Land of More and More” is the creation of published ... Indiana where he works with the children’s ministry department. , Michael says that ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: